Patients with myeloma and loved ones, please join us on June 22nd in Charlotte for a terrific International Myeloma Foundation Regional Community Workshop! https://t.co/1bp9tSOEee(IMF,2024%2C%20in%20Charlotte%2C%20NC.

NEWS: We are excited to announce that the first patient has been dosed in the Phase 3 study evaluating an investigational BCMA-directed bispecific antibody for patients with relapsed/refractory #MultipleMyeloma. Read more: https://t.co/n9RanaEqo2. @PlasmaCellPete #mmsm

When #ASCO24 tells you that non-profits are not allowed to bring a media team to the conference you go to #EHA24 to record myeloma news video instead! Headed to Madrid early to do some sightseeing before the conference. Who else will be there? #mmsm

Join me and my dear colleagues Saad Usmani and Noopur Raje as we discuss the rapidly changing landscape of newly diagnosed myeloma. We welcome you to join us at this PER satellite symposium Sunday night , Hilton Chicago, at the annual ASCO meeting! https://t.co/WZ8rvj5Kwa

Achievement of MRD negativity 1 year after transplant is associated with improved progression-free and overall survival. Congrats to Dr. Pasquini and the BMT CTN 0702 / STaMINA investigators! https://t.co/3QCtA1L6Mj

The Charlotte HealthTree Myeloma Roundtable is 3 days away!!! Patients and loved ones, we look forward to seeing you for a great day of myeloma learning! https://t.co/sCbTxs36D3

This link should work;) https://t.co/sCbTxs36D3

Patients, caregivers, and loved ones, In collaboration with HealthTree, we are sponsoring a myeloma round table on May 4th in Charlotte NC. It should be a great day, and we look forward to seeing you there! https://t.co/uJ6rwlVV9M$

Levine Cancer Institute partnering with the MMRF to cure myeloma. Thanks to the MMRF team for their support of our patients! We are getting closer!!! ⁦@AtrashShebli⁩ ⁦@LevineCancer⁩ ⁦@AtriumHealth⁩ ⁦@theMMRF⁩

The Levine Cancer Institute Myeloma Team with Shebli Atrash and Plasma Cell Pete leading the charge, running for the cure at the Charlotte MMRF run on Sept. 16!

Talquetamab, a first-in-class GPRC5D -targeted bispecific antibody, has been approved by the FDA. This is a major step forward for the multiple myeloma field and a huge win for patients with relapsed / refractory disease!!!

With my plasma cellebrities…enjoying the science, loving the cameraderie @ninashah33 @szusmani @jmikhaelmd @EmilyMikhael @JatinShahMD @LevineCancer

Fantastic results and a wonderful presentation. We are very proud of you at Levine Cancer Institute!!! @LevineCancer @WakeCancer #lymsm

Proud of my colleague, friend and rising #mmsm leader, delivering a perfect presentation of revolutionary therapy ⁦@EHA_Hematology⁩ ⁦@SusanBal9⁩ ⁦@ONealCancerUAB⁩ ⁦@uabmedicine⁩ 😊

The IMF and m-power are coming to Charlotte on April 1st! We would love to have you join us for this important event!

Most of my patients are triple class refractory after 3 lines of therapy. Would love to see a BCMA-targeted T cell redirecting option for patients who have received less than 4 prior lines of therapy. Nonetheless, today’s announcement from the FDA is great news for patients!

Teclistamab is now FDA approved!!! Great news and an important off-the-shelf option for our patients!!!

Not too late to join the Levine Cancer Institute’s 2nd Annual Charlotte Hematologic Malignancies Congress virtually on 10/21 and 10/22! Terrific lineup of speakers! Register at

LCI’s 2nd Annual Heme Malignancies Congress is fast approaching on 10/21 and 10/22! The F2F event is fully registered but we encourage virtual participation, too! Register now and get up-to-date with the latest updates in blood cancers from world experts!

On October 21 and 22, Levine Cancer Institute will be hosting its 2nd Annual Charlotte Hematologic Malignancies Congress. We have an all-star KOL cast presenting / debating the latest data! Join us face to face or virtually for this incredible opportunity!